Results 11 to 20 of about 38,056 (264)
Biomarkers of chondrosarcoma [PDF]
Journal of Clinical Pathology, 2018 Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour.
Wonju Jeong, Ha-Jeong Kim
openaire +4 more sources
Cell Communication and Signaling, 2019 Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used ...
Zhengxiao Ouyang +6 more
doaj +2 more sources
Chondrosarcoma: A Clinical Review
Journal of Clinical Medicine, 2023 Chondrosarcomas are a diverse group of malignant cartilaginous matrix-producing neoplasms. Conventional chondrosarcomas are a continuum of disease based on the biologic activity of the tumor.
A. Gazendam +3 more
semanticscholar +1 more source
Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings
Cancers, 2023 Simple Summary Chondrosarcomas are a very heterogeneous group of cartilage-forming tumors that comprise approximately one-third of all malignant bone tumors.
Jun-Ho Kim, S. Lee
semanticscholar +1 more source
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
International Journal of Molecular Sciences, 2022 Simple Summary Chondrosarcomas develop chemoresistance to standard anticancer drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve the clinical outcomes of chondrosarcoma, new treatment approaches, such as molecule-
S. Miwa +5 more
semanticscholar +1 more source
Chondrosarcoma-from Molecular Pathology to Novel Therapies
Cancers, 2021 Simple Summary Chondrosarcoma (CHS) belongs to a broad group of sarcomas and is the second most frequent malignant bone tumor. Due to its resistance to chemo- and radiotherapy, treatment of this tumor is complicated and is mainly limited to surgery.
Agnieszka E Zając +10 more
semanticscholar +1 more source
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
Cancer Medicine, 2021 IDH1/2 mutations are prevalent in cartilaginous tumors including chondrosarcoma. This meta‐analysis using individual patient data (IPD) aimed to investigate the clinical and prognostic association of these mutations in chondrosarcoma patients.
H. Vuong, T. Ngo, I. Dunn
semanticscholar +1 more source
TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma
Modern Pathology, 2021 Chondrosarcomas are the second most common malignant bone tumor. Activating promoter mutations in telomerase reverse transcriptase (TERT) was recently described by us and others as a frequent mutation in high-grade chondrosarcoma.
Yifan Zhang +8 more
semanticscholar +1 more source
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
Cancers, 2021 Simple Summary Chordomas and chondrosarcomas are rare tumors that can occur within the skull base and spinal column and are often resistant to chemotherapy and radiation.
Jeffrey I. Traylor +4 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2021 Chondrosarcoma is a malignant bone tumor that is characterized by high metastatic potential and marked resistance to radiation and chemotherapy. The knowledge that adipokines facilitate the initiation, progression, metastasis, and treatment resistance of
Shih-Ya Hung +10 more
semanticscholar +1 more source